Efficacy markers in depression.
Current antidepressant agents are similar in efficacy to the original drugs discovered in the 1950s. The development of new treatments for depression is, however, limited by the absence of validated human biomarker models to predict efficacy, clinical profile and dosing. Such models need to meet key...
主要な著者: | Harmer, C, Cowen, P, Goodwin, G |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2011
|
類似資料
-
Efficacy markers in depression
著者:: Harmer, C, 等
出版事項: (2011) -
Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms.
著者:: Hayward, G, 等
出版事項: (2005) -
Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms
著者:: Hayward, G, 等
出版事項: (2005) -
Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression.
著者:: Bhagwagar, Z, 等
出版事項: (2004) -
Elevated waking cortisol levels in neuroticism: A biological vulnerability factor for depressive disorders?
著者:: Portella, M, 等
出版事項: (2004)